ARTICLE | Company News
Editas scores hat trick of CRISPR-Cas9 deals
December 2, 2014 3:36 AM UTC
Editas Medicine (Cambridge, Mass.) obtained exclusive licenses to CRISPR- Cas9 and TALEN gene editing technologies from three research institutions.
Two of the new agreements involved Editas' own scientific co-founders: one a joint license from the Broad Institute of MIT and Harvard, and Harvard University alone; the other from Massachusetts General Hospital (MGH). The third is with Duke University. ...